Posts from ‘January, 2009’

NEW BRUNSWICK, N.J., Jan. 23 (HSMN NewsFeed) — Johnson & Johnson (NYSE: JNJ ) today announced the expiration of the subsequent offering period of the cash tender offer through its wholly owned subsidiary, Maple Merger Sub, Inc., for all excellent shar…
Devices, Mergers & Acquisitions
Johnson & Johnson, Mentor Corp

Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury MENLO PARK, Calif., January 23, 2009 - (HSMN NewsFeed) - Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the comp…
Regenerative Medicine, Neurosrugery, FDA
Geron Corp, GRNOPC1, spinal cord injury, human embryonic stem cell

PITTSBURGH, Jan. 23 (HSMN NewsFeed) — Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application…
Biopharmaceuticals, Generics, FDA
Mylan, Omeprazole, AstraZeneca, Prilosec, gastroesophageal reflux disease

Marketing to Begin Immediately HAYWARD, Calif.–(HSMN NewsFeed)– IMPAX Laboratories, Inc. (OTC: IPXL), through its generic drug division Global Pharmaceuticals, announced that yesterday the U.S. Food and Drug Administration (FDA) granted final approval…
Biopharmaceuticals, Generics, FDA
IMPAX Laboratories, Omeprazole, AstraZeneca, Prilosec, gastroesophageal reflux

- Two-Year Primary Efficacy Endpoint of CLARITY Trial met: 58% Relative Reduction in Annualized Relapse Rate in the low Total Dose Treatment Group and 55% in the High Total Dose Treatment Group - Submission for Registration of Cladribine Tablets Planned fo…
Biopharmaceuticals, Neurology
Merck Serono, Merck KGaA, cladribine, multiple sclerosis, CLARITY study

Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury MENLO PARK, Calif., January 23, 2009 - (HSMN NewsFeed) - Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the comp…
Regenerative Medicine, Neurosrugery, FDA
Geron Corp, GRNOPC1, spinal cord injury, human embryonic stem cell

Antimicrobial and Oncology Lead Compounds to be Taken Through Early Clinical Development TROMS0, Norway, January 22 (HSMN NewsFeed) — The Scandinavian-based drug development company Lytix Biopharma today announced the closure of a successful funding …
Biopharmaceuticals, Venture Capital
Lytix Biopharma, antibiotic

EDMONTON, Jan. 22 - (HSMN NewsFeed) - (ISA:TSX): Isotechnika Inc. announced today that its partner, Atrium Medical Corporation has completed patient enrollment for their CONFIRM 1, First-in-Man (FIM) drug coated coronary stent clinical trial evaluating Atr…
Devices, Interventional Cardiology
Isotechnika, Atrium Medical, CONFIRM 1, CINATRA, voclosporin, stent, FIM trial

LOS ANGELES, CA–Jan 22, 2009 — Cardo Clinical (OTC BB:CDOM.OB ), a company engaged in the development of orthopedic medical devices, announces the initial release of its Press-Fit Total Hip system. The Press-Fit Total Hip system incorporates a dual taper …
Devices, Orthopaedic
Cardo Medical, Press-Fit, Total Hip, hip replacement

First and Only Biologic Approved with Infrequent, Every Twelve-Week Maintenance Dosing BEERSE, Belgium, Jan. 22 (HSMN NewsFeed) — Janssen-Cilag announced today that STELARA(TM) (ustekinumab), the first in a new class of biologics, has been approved b…
Biopharmaceuticals, Regulatory
Janssen-Cilag, STELARA, ustekinumab, severe plaque psoriasis, psoriasis